Results of Oraya Threaperutics’ INTREPID study show that a single does of Oraya Therapy significantly reduces the need for anti-VEGF injections for patients with wet AMD.
The study, which was published online in the journal Opthalmology this month (April 18), enrolled a total of 230 patients from 21 sites across five European countries. The investigators evaluated the effectiveness and safety of Oraya Therapy – a one-time radiation therapy – in conjunction with as-needed anti-VEGF injections.
The researchers reported that patients who had previously been treated with anti-VEGF for up to three years experienced a 32% reduction of injections and substantially drier retinas with Oraya Therapy compared with the control group. Moreover 25% of Oraya Therapy patients needed no further injections.
Among the best responders to Oraya therapy, there was a 52% decrease in injections.
“The results of the INTREPID study reported to date are encouraging for clinicians and individuals with wet AMD,” said lead investigator, Timothy Jackson, from King’s College Hospital in London. “The prospect of maintaining vision while needing fewer eye injections will appeal to any patient receiving anti-VEGF therapy, and for certain subsets in the trial there is the added advantage of an improved visual outcome.”
Oraya Therapeutics CEO, Jim Taylor, added: “It is rare for a new therapy to demonstrate improved patient outcomes while simultaneously offering the potential to significantly reduce treatment burden and costs.”
Oraya Therapy involves a low-voltage X-ray source along with advanced robotics, laser-guided positioning system and a patented methodology for eye stabilization and tracking.
The procedure can be delivered in an outpatient setting, averages about 20 minutes and requires no post-treatment recovery period before resuming normal activity.
